FR2873694B1 - Nouveaux aza-indoles inhibiteurs de la mtp et apob - Google Patents

Nouveaux aza-indoles inhibiteurs de la mtp et apob

Info

Publication number
FR2873694B1
FR2873694B1 FR0408302A FR0408302A FR2873694B1 FR 2873694 B1 FR2873694 B1 FR 2873694B1 FR 0408302 A FR0408302 A FR 0408302A FR 0408302 A FR0408302 A FR 0408302A FR 2873694 B1 FR2873694 B1 FR 2873694B1
Authority
FR
France
Prior art keywords
apob
mtp
indoles
inhibitors
new aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0408302A
Other languages
English (en)
Other versions
FR2873694A1 (fr
Inventor
Alyx Caroline Guevel
Catherine Vidal
Bruno Roux
Olivier Chevreuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0408302A priority Critical patent/FR2873694B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to SI200530353T priority patent/SI1771446T1/sl
Priority to AT05754288T priority patent/ATE398126T1/de
Priority to PT05754288T priority patent/PT1771446E/pt
Priority to AU2005266662A priority patent/AU2005266662B2/en
Priority to JP2007522937A priority patent/JP5161569B2/ja
Priority to CA2575223A priority patent/CA2575223C/fr
Priority to ES05754288T priority patent/ES2308510T3/es
Priority to EP05754288A priority patent/EP1771446B1/fr
Priority to PCT/EP2005/006930 priority patent/WO2006010423A2/fr
Priority to DK05754288T priority patent/DK1771446T3/da
Priority to DE602005007494T priority patent/DE602005007494D1/de
Priority to US11/658,596 priority patent/US7838533B2/en
Priority to PL05754288T priority patent/PL1771446T3/pl
Priority to ARP050103117A priority patent/AR050436A1/es
Publication of FR2873694A1 publication Critical patent/FR2873694A1/fr
Application granted granted Critical
Publication of FR2873694B1 publication Critical patent/FR2873694B1/fr
Priority to CY20081100933T priority patent/CY1108306T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
FR0408302A 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob Expired - Fee Related FR2873694B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob
DK05754288T DK1771446T3 (da) 2004-07-27 2005-06-28 Azaindolinhibitorer af MTP og APOB
PT05754288T PT1771446E (pt) 2004-07-27 2005-06-28 Novos inibidores azaindolo da mtp e apob
AU2005266662A AU2005266662B2 (en) 2004-07-27 2005-06-28 Azaindole inhibitors of MTP and ApoB
JP2007522937A JP5161569B2 (ja) 2004-07-27 2005-06-28 ＭＴＰおよびＡｐｏＢの新規なアザインドール阻害剤
CA2575223A CA2575223C (fr) 2004-07-27 2005-06-28 Nouveaux composes d'azaindole inhibiteurs de mtp et d'apob
ES05754288T ES2308510T3 (es) 2004-07-27 2005-06-28 Inhibidores azaindolicos de mtp y apob.
EP05754288A EP1771446B1 (fr) 2004-07-27 2005-06-28 Composes d'azaindole inhibiteurs de mtp et d'apob
SI200530353T SI1771446T1 (sl) 2004-07-27 2005-06-28 Azaindolni zaviralci mtp-ja in apob-ja
AT05754288T ATE398126T1 (de) 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob
DE602005007494T DE602005007494D1 (de) 2004-07-27 2005-06-28 Azaindolinhibitoren von mtp und apob
US11/658,596 US7838533B2 (en) 2004-07-27 2005-06-28 Azaindole inhibitors of MTP and ApoB
PL05754288T PL1771446T3 (pl) 2004-07-27 2005-06-28 Azaindolowe inhibitory MTP oraz ApoB
PCT/EP2005/006930 WO2006010423A2 (fr) 2004-07-27 2005-06-28 Nouveaux composes d'azaindole inhibiteurs de mtp et d'apob
ARP050103117A AR050436A1 (es) 2004-07-27 2005-07-27 Inhibidores de azaindol de mtp y apob
CY20081100933T CY1108306T1 (el) 2004-07-27 2008-09-02 Αναστολεις αζαϊνδολιου των mtp και apob

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408302A FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob

Publications (2)

Publication Number Publication Date
FR2873694A1 FR2873694A1 (fr) 2006-02-03
FR2873694B1 true FR2873694B1 (fr) 2006-12-08

Family

ID=34948943

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408302A Expired - Fee Related FR2873694B1 (fr) 2004-07-27 2004-07-27 Nouveaux aza-indoles inhibiteurs de la mtp et apob

Country Status (16)

Country Link
US (1) US7838533B2 (fr)
EP (1) EP1771446B1 (fr)
JP (1) JP5161569B2 (fr)
AR (1) AR050436A1 (fr)
AT (1) ATE398126T1 (fr)
AU (1) AU2005266662B2 (fr)
CA (1) CA2575223C (fr)
CY (1) CY1108306T1 (fr)
DE (1) DE602005007494D1 (fr)
DK (1) DK1771446T3 (fr)
ES (1) ES2308510T3 (fr)
FR (1) FR2873694B1 (fr)
PL (1) PL1771446T3 (fr)
PT (1) PT1771446E (fr)
SI (1) SI1771446T1 (fr)
WO (1) WO2006010423A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
CN102851291B (zh) 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (fr) 2007-03-22 2008-09-25 Santaris Pharma A/S Composes arn antagonistes pour l'inhibition de l'expression de l'apo-b100
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
CA2717792A1 (fr) 2008-03-07 2009-09-11 Santaris Pharma A/S Compositions pharmaceutiques pour le traitement de maladies associees aux microarn
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010012667A1 (fr) 2008-08-01 2010-02-04 Santaris Pharma A/S Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
EP2456870A1 (fr) 2009-07-21 2012-05-30 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
CA2877474A1 (fr) * 2011-06-20 2012-12-27 Myrexis, Inc. Composes et ses utilisations therapeutiques
EP3591054A1 (fr) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Oligomères et conjugués antisens ciblant pcsk9
CN113874015A (zh) 2018-12-21 2021-12-31 细胞基因公司 Ripk2的噻吩并吡啶抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
SI1404653T1 (sl) * 2001-06-28 2008-12-31 Pfizer Prod Inc S triamidom substituirani indoli, benzofurani in benzotiofeni kot zaviralci mikrosomske prenašalnebeljakovine za trigliceride (MTP) in/ali izločanja apolipoproteina B (APO B)
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
KR20050008752A (ko) 2002-05-31 2005-01-21 야마노우치세이야쿠 가부시키가이샤 테트라히드로피란 유도체
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体

Also Published As

Publication number Publication date
AR050436A1 (es) 2006-10-25
US20090036481A1 (en) 2009-02-05
PL1771446T3 (pl) 2008-10-31
PT1771446E (pt) 2008-09-17
JP2008508198A (ja) 2008-03-21
CA2575223A1 (fr) 2006-02-02
JP5161569B2 (ja) 2013-03-13
DE602005007494D1 (de) 2008-07-24
ES2308510T3 (es) 2008-12-01
ATE398126T1 (de) 2008-07-15
FR2873694A1 (fr) 2006-02-03
SI1771446T1 (sl) 2008-10-31
AU2005266662B2 (en) 2011-04-21
US7838533B2 (en) 2010-11-23
DK1771446T3 (da) 2008-09-22
EP1771446A2 (fr) 2007-04-11
CY1108306T1 (el) 2014-02-12
CA2575223C (fr) 2013-08-06
AU2005266662A1 (en) 2006-02-02
WO2006010423A3 (fr) 2006-03-02
WO2006010423A2 (fr) 2006-02-02
EP1771446B1 (fr) 2008-06-11

Similar Documents

Publication Publication Date Title
FR2873694B1 (fr) Nouveaux aza-indoles inhibiteurs de la mtp et apob
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK2302055T3 (da) Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
DE602005011285D1 (de) Formmasse von polymer
DK1720866T3 (da) Fremgangsmåde
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE521604T1 (de) N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
SMAP200700023A (it) Dispositivi e metodi per iniezioni di medicinali
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
DE602005019971D1 (de) Inhibitoren von cysteinprotease
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1831605T3 (da) Fremgangsmåde vedrørende forbrænding
BRPI0509054A (pt) óculos e método de fabricação dos mesmos
FI20030261A (fi) Iskulaite
ITTO20050555A1 (it) Dispositivo e metodo di attuazione
FR2884820B1 (fr) Nouveaux inhibiteurs specifiques de la caspase-10
FR2878522B1 (fr) Nouveaux inhibiteurs specifiques de la caspas-10
FR2877833B1 (fr) Correcteur de lordoses
ITUD20040009A1 (it) Dispositivo e procedimento di bobinatura di
FR2855730B1 (fr) Surmatelas de relaxation
UA9216S (uk) Комплект патерлиць і хреста

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140331